Red Violet's 2Q26 beat reinforces growth but leaves valuation and mix concerns in focus

What happened

Red Violet (RDVT) reported a strong second quarter of 2026, with EPS beating estimates by 62% and record client growth, underscoring robust demand for its identity and risk-data software. The company's operating leverage drove adjusted EBITDA up 48% and pushed free cash flow to record levels, while management highlighted a clean balance sheet and a new $100 million capital raise. However, the quarter did not directly address the key risks identified in our prior analysis: contractual revenue mix declined modestly to 75% in 2Q26, and the IDI real-estate vertical (excluding FOREWARN) continued to face housing-related headwinds. While active share repurchases and the capital raise bolster financial flexibility, the stock's valuation remains elevated at roughly 51 times earnings and 30 times EBITDA, offering little margin of safety if growth decelerates. The public-sector opportunity via the Carahsoft GSA Schedule still lacks named agency wins, leaving a critical pillar of the bull thesis unproven despite the upbeat quarterly report.

Implication

The 2Q26 results demonstrate that Red Violet's growth engine remains intact, with expanding margins and record cash generation supporting the premium valuation. Nevertheless, the stock still trades at a P/E of over 50 and EV/EBITDA near 30, leaving limited room for error if housing-related softness or competitive pressures intensify. The $100 million capital raise, while strengthening the balance sheet, may also dilute existing shareholders and signals that management sees opportunities for reinvestment that are not yet reflected in the base case. Critical milestones to watch over the next two quarters include stabilization of the contractual revenue mix above 70% and tangible public-sector contract wins through the GSA Schedule. Until those uncertainties are resolved, we maintain a WAIT rating, preferring to accumulate on weakness near $38 or upon evidence that the public-sector channel is converting meaningful revenue.

Thesis delta

The strong 2Q26 beat partially validates the bull case, but our WAIT thesis remains in place because the quarter did not resolve the key risks of contractual mix erosion and lack of public-sector wins. The $100 million capital raise adds financial firepower but also introduces dilution uncertainty and suggests the company may be planning larger investments that could pressure near-term margins. We are holding our attractive entry near $38 and will reassess if the next quarter shows sustained 25% revenue growth and named public-sector awards.